inōtiv Corporate Presentation June 2023

Investment Highlights Opportunities for improvements in cash position with anticipated higher EBITDA margins as site optimization savings are realized and start-up costs fall-off, and from proceeds of small asset sales when completed 阖 44 Sil A leading midsized CRO, our client base has expanded to more than 3,500 leading pharma, biotech and academic institutions since committing to a fast growth strategy and corporate reorganization starting in 2018 Investments in facilities and the consolidation of overlapping facilities completed in 2023 and one consolidation to be completed in 2024, and are expected to generate up to $20M in efficiencies; long-term adjusted EBITDA margin targets are projected to be in the range of 18% - 22% Through organic growth and acquisitions from 2018 to present, Inotiv has transformed into a leading full service CRO provider, offering clients nimble solutions and custom capabilities from discovery services to clinical development in addition to large and small animal research science models. Future organic growth and improved operating leverage provides opportunity for enhanced margins Inotiv is a major provider of animal models in the U.S. and at present, is working to address the shortage of research models including NHPS M We stress sustainable practices as the market for research models have tightened, while continuing to focus on maintaining our gross margins 4 | Note: Adjusted EBITDA margin targets are provided on a non-GAAP basis. The Company cannot reconcile this guidance to target net income/loss margin without unreasonable effort because certain items that impact net income/loss margin are out of the Company's control and/or cannot be reasonably predicted at this time, which unavailable information could have a significant impact on the Company's GAAP financial results. CORPORATE PRESENTATION inōtiv analyze, answer. advance.

View entire presentation